For the Inventor, By the Inventor

Enter assignee name

Tigenix, S.a.u.

USPTO Granted Patents = 12

CIPO Patents = 1

EPO Patents = 19

Trademarks = 4

Forward Citations = 48

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

María Gema Fernández Miguel (4 out of 6 patents)

Rosa Ana García Castro (4 out of 6 patents)

Mariano García Arranz (4 out of 6 patents)

4. Damián García Olmo (4 out of 6 patents)

5. Manuel Angel González De La Peña (4 out of 5 patents)

6. Dirk Büscher (3 out of 4 patents)

7. Damian Garcia-Olmo (2 out of 2 patents)

8. Manuel Ángel González De La Peña (2 out of 3 patents)

9. Olga De La Rosa (2 out of 6 patents)

10. Wilfried Dalemans (2 out of 4 patents)

11. Eleuterio Lombardo (2 out of 5 patents)

12. Mario Delgado Mora (2 out of 2 patents)

13. Mariano Garcia Arranz (2 out of 2 patents)

14. Eduardo Bravo (1 out of 3 patents)

15. Maria Pascual (1 out of 3 patents)

12 patents: Sort by Forward Citations

1. 12186344 - Cell populations having immunoregulatory activity, method for isolation and uses (2025-01-07),

2. 11253632 - Biomaterial for suturing (2022-02-22),

3. 10780132 - Use of adipose tissue-derived stromal stem cells in treating fistula (2020-09-22),

4. 10758575 - Use of adipose tissue-derived stromal stem cells in treating fistula (2020-09-01),

5. 10746729 - Biomarkers for determining the clinical response to cell therapy (2020-08-18),

6. 10729726 - Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue (2020-08-04),

7. 10660920 - Lymphocyte biomarkers for determining the clinical response to cell therapy (2020-05-26),

8. 10548924 - Use of adipose tissue-derived stromal stem cells in treating fistula (2020-02-04),

9. 10357518 - Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease (2019-07-23),

10. 9943550 - Cell populations having immunoregulatory activity, method for isolation and uses (2018-04-17),

11. 8999709 - Use of adipose tissue-derived stromal stem cells in treating fistula (2015-04-07),

12. 8679834 - Methods and compositions for use in cellular therapies (2014-03-25),

Tigenix, S.A.U. is a biopharmaceutical company that specializes in the development and commercialization of cell therapies. They focus on treating severe medical conditions by harnessing the regenerative potential of cells. With a dedication to innovation and a strong product pipeline, Tigenix aims to improve patients' quality of life. For more information, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

12 Patents

#26 in Madrid

#169 in Spain

#46,685 in the World

Tigenix, S.a.u.

Forward Citations = 48

20 inventors:

María Gema Fernández Miguel (4 out of 6 patents)

Rosa Ana García Castro (4 out of 6 patents)

Mariano García Arranz (4 out of 6 patents)

4. Damián García Olmo (4 out of 6 patents)

5. Manuel Angel González De La Peña (4 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…